Pulmonary Hypertension: Intensification and Personalisation of Combination Rx

The goal of this clinical trial is to evaluate the capacity of implantable/remote technology for early evaluation of drug therapies in patients with pulmonary arterial hypertension (PAH). The main question it aims to answer is whether structured changes in clinical therapy will be detectable using implanted regulatory approved devices. Participants will will be implanted with approved medical devices and will enter into a study of approved drugs to assess physiology, activity and patient reported quality-of-life (QoL) outcomes. Researchers will compare two therapeutic strategies in each individual patient to see if the study design provides enough evidence to personalise drug treatment plans.

NCT Number	NCT05825417
Lead Sponsor	Sheffield Teaching Hospitals NHS Foundation Trust Collaborators: University of Glasgow, University of Sheffield, University of Newcastle Upon-Tyne, University of Cambridge
Conditions	Pulmonary Arterial Hypertension
Enrollment	70 participants
Start Date	2023-06-14
Primary Completion	2028-01 (estimated)
Study Completion	2028-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-07